Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $871 | $1,560 | $1,758 | $2,663 |
| - Cash | $277 | $153 | $104 | $586 |
| + Debt | $639 | $586 | $763 | $1,129 |
| Enterprise Value | $1,233 | $1,992 | $2,417 | $3,207 |
| Revenue | $701 | $675 | $667 | $542 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Gross Profit | $531 | $490 | $468 | $401 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| EBITDA | $29 | $155 | $140 | $114 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |
| Net Income | -$100 | $42 | $16 | $42 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| % Growth | -341.6% | 161.8% | -63% | – |
| Operating Cash Flow | $189 | $155 | $145 | $126 |
| Capital Expenditures | -$11 | -$15 | -$30 | -$46 |
| Free Cash Flow | $179 | $139 | $115 | $80 |